Graham G. Walmsley — SEC Form 4 filings
SEC reporting owner CIK 1777517. 14 Form 4 filings on record with FilingPulse; latest filed 2026-06-23.
Transaction summary — filings shown
Covers all 14 filings on record, filed 2024-06-06 to 2026-06-23. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 6 legs across 4 filings — 1,801,522 shares, $27,848,195 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 6 legs across 4 filings — 3,751,522 shares, $44,357,774 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 19.
- Largest priced transaction: sale of 700,000 shares @ $14.85 ($10,395,000) in Olema Pharmaceuticals, Inc., filed 2024-11-26.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | Director | 8 | 2 legs · 1,401,522 sh · $9,460,274 | 6 legs · 3,751,522 sh · $44,357,774 | 3 |
| Akero Therapeutics, Inc. (AKRO) | Director | 6 | 4 legs · 400,000 sh · $18,387,921 | — | 16 |
Form 4 filings — Graham G. Walmsley
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-23 | 4 | Olema Pharmaceuticals, Inc. (OLMA) | Grant/award (A): 29,500 (derivative) @ $0 | EDGAR |
| 2025-12-09 | 4 | Akero Therapeutics, Inc. (AKRO) | Disposition to issuer (D): 93,000 · Disposition to issuer (D): 1,200,000 · Disposition to issuer (D): 9,398 · Disposition to issuer (D): 15,000 (derivative) | EDGAR |
| 2025-10-10 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 26,000 @ $23.02 · Option exercise (M): 15,000 @ $8.13 · Option exercise (M): 13,000 @ $26.32 · Option exercise (M): 13,000 @ $25.20 · Option exercise (M): 23,832 @ $19.97 · Option exercise (M): 26,000 (derivative) @ $0 · +4 more | EDGAR |
| 2025-06-13 | 4 | Olema Pharmaceuticals, Inc. (OLMA) | Grant/award (A): 24,150 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 9,398 @ $0 | EDGAR |
| 2025-05-13 | 4/A | Olema Pharmaceuticals, Inc. (OLMA) | Holdings only — no transactions reported | EDGAR |
| 2025-03-27 | 4 | Akero Therapeutics, Inc. (AKRO) | Purchase (P): 91,309 @ $44.75 · Purchase (P): 58,691 @ $43.01 · Purchase (P): 50,000 @ $43.55 | EDGAR |
| 2025-02-07 | 4 | Akero Therapeutics, Inc. (AKRO) | Purchase (P): 200,000 @ $48 | EDGAR |
| 2024-12-18 | 4/A | Olema Pharmaceuticals, Inc. (OLMA) | Sale (S): 700,761 @ $6.75 · Purchase (P): 700,761 @ $6.75 | EDGAR |
| 2024-12-17 | 4 | Olema Pharmaceuticals, Inc. (OLMA) | Sale (S): 700,761 @ $6.75 · Purchase (P): 700,761 @ $6.75 | EDGAR |
| 2024-11-26 | 4/A | Olema Pharmaceuticals, Inc. (OLMA) | Sale (S): 700,000 @ $14.85 · Sale (S): 475,000 @ $14.85 | EDGAR |
| 2024-06-18 | 4 | Olema Pharmaceuticals, Inc. (OLMA) | Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2024-06-11 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | Olema Pharmaceuticals, Inc. (OLMA) | Sale (S): 700,000 @ $14.85 · Sale (S): 475,000 @ $14.85 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1777517 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →